Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis

Abstract

The objective of this study was to investigate the usefulness of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in predicting short-term therapeutic response to methotrexate (MTX) in rheumatoid arthritis (RA). Patients with active RA, with Disease Activity Score-28 joints (DAS-28) >3.2, starting oral MTX, were included. We measured at baseline, 3 and 6 mo: DAS-28, Health Assessment Questionnaire-Disability Index (HAQ-DI), patient's perception of disease severity, morning stiffness and pain, as well as modifications in sTREM-1 levels. A reduction in DAS-28 > 1.2 at 3 or 6 mo was considered adequate response. A significant decrease in DAS-28 was observed at 3 and 6 mo. HAQ-DI also decreased at 3 and 6 mo. No significant changes were observed in sTREM-1 levels at 3 or 6 mo. Using as cut-off a baseline value of sTREM-1 levels > 390 pg/ml, we obtained low values of sensitivity (61.5%), specificity (59.3%), positive predictive value (59.3%) and negative predictive value (61.5%) for adequate response to MTX at 3 mo. We found no clinical value of sTREM-1 levels in predicting therapeutic response to MTX in RA. Further studies should evaluate if sTREM-1 levels are predictive for other outcomes, including higher structural damage or good response to biologics.

Elevated serum TREM-1 is associated with periodontitis and disease activity in rheumatoid arthritis

“…Thus far, to our knowledge, only two studies have investigated serum levels of TREM-1 relative to MTX treatment in RA patients. In contrast to Gamez-Nava et al 48 , who failed to identify differences in serum TREM-1 www.nature.com/scientificreports/ levels relative to MTX use, our findings demonstrated significantly decreased serum TREM-1 levels in RA patients on MTX as compared to those on other csDMARDs. Similar trends were observed in RA patients stratified by the absence or presence of periodontitis.…”

Association of soluble triggering receptor expressed on myeloid cells‐1 with rheumatoid arthritis in iraqi patients: A case-control study

“…This soluble form acts as a decoy receptor for the natural TREM-1 ligand and dampens the activation of TREM-1. As a result, the cascade of proinflammatory processes linked to this binding process is diminished because sTREM-1 competes with the ligands of TREM-1 (11). The toll-like receptor-induced inflammatory response is potently stimulated by the TREM-1.…”

“…This specific subtype of TREM-1 can be discharged into the bloodstream or other bodily fluids after an illness (10). The natural ligand of TREM-1 works as a decoy receptor for the soluble version of TREM-1, which lessens TREM-1 activation (11). As a result, sTREM-1 competes with TREM-1's ligands, which reduces the proinflammatory cascade brought on by this interaction.…”

Identification of Novel Targets of Knee Osteoarthritis Shared by Cartilage and Synovial Tissue

“…For the therapeutic drug development, targeted photodynamic therapy (tPDT) using the anti-FAP antibody 28H1 coupled to the photosensitizer IRDye700DX moderately delayed the collagen-induced arthritis development in mice [ 42 ]. Meanwhile, TREM-1 has also been identified as a biomarker of synovitis in RA [ 43 ] and predicting the therapeutic response to methotrexate in RA [ 44 ]. Inhibiting the expression of TREM-1 could suppress the chondrocyte injury induce by IL-1β in vitro [ 45 ], and ameliorate collagen-induced arthritis and protect bone and cartilage damage in vivo [ 46 ].…”